Senior executive assistant [h1.location_city]

The Executive Assistant is responsible for providing administrative and secretarial support to the Company's Leadership Team. This role is a key member of the administrative team and leads all administrative efforts for Elicio's Leadership team.

The person in this role will coordinate a high level of appointment scheduling, meeting notation, travel arrangements, expense reimbursement, meeting coordination, preparing presentation materials, and assisting with office and company operational needs.

Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts with additional staff functioning in a virtual based environment from the Greater Boston area and throughout the United States.

Major Duties / Responsibilities

• Provide administrative support to Elicio's Leadership Team
• Proactively manager calendars with the ability to schedule and prioritize meetings, resolve schedule conflicts, and ensure efficient and positive experiences for attendees
• Manage and prioritize internal and external communications for key stakeholders
• Handle confidential and proprietary information with discretion
• Manage specific vendors
• Coordinate both onsite and offsite meetings for the Leadership team
• Coordinate and organize travel, hotel accommodations, car service, preparation of itineraries / materials, etc.
• Schedule numerous weekly meetings
• Assist with company administrative duties, including office management / Human Resources tasks as needs arise
• Responsible for taking notes and minutes in key meetings
• Act as a point person for visitors, executives, and investors

Education & Professional Experience

Required :

Skills

Working Conditions : Busy office / laboratory environment with frequent deadlines and interruptions

Travel : Travel is not required

Physical Requirements : Subject to periods of sitting or standing, vision is required to monitor data.

Work Location : This role can be onsite, hybrid or remote.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq : ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies to prevent the recurrence of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio's Amphiphile ("AMP") technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio's ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy. Elicio's pipeline includes additional off-the-shelf therapeutic cancer vaccines, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

About the Amphiphile Platform

Elicio's proprietary AMP platform delivers investigational immunotherapeutics directly to the "brain center" of the immune system-the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based on preclinical studies.

Elicio's AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.

The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue.